Pretreatment levels of serum soluble interleukin-2 receptor are useful in selecting the treatment regimen for newly diagnosed advanced-stage follicular lymphoma with low tumor burden
暂无分享，去创建一个
M. Kawakami | J. Ishikawa | Y. Moriyama | Ryoto Sakaniwa | H. Shibayama | T. Karasuno | T. Kamae | S. Ueda | S. Kosugi | M. Nakagawa | H. Sugahara | M. Iida | K. Nozaki | Y. Azenishi | T. Kitamura
[1] M. Kawakami,et al. Pretreatment serum soluble interleukin-2 receptor level predicts survival in patients with newly diagnosed follicular lymphoma , 2020, Leukemia & lymphoma.
[2] Y. Kanda,et al. Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.
[3] G. Salles,et al. Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up. , 2012 .
[4] G. Salles,et al. Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] H. Tilly,et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.